Literature DB >> 21997275

Soluble expression of recombinant human CD137 ligand in Escherichia coli by co-expression of chaperones.

Shuzhen Wang1, Aimin Tan, Junfang Lv, Peng Wang, Xiaojin Yin, Yijun Chen.   

Abstract

CD137 ligand (CD137L) is a member of the tumor-necrosis factor superfamily that binds CD137 to provide positive co-stimulatory signals for T cells activation. Co-stimulation through CD137/CD137L has become one of the promising approaches for cancer therapy. Previous reports have shown that CD137L expressed in Escherichia coli resulted in inclusion bodies or low yield. In this study, the effects of five different chaperone teams on the soluble expression of recombinant human CD137L protein were explored and analyzed. The poor expression of CD137L in the cytoplasm of E. coli was improved significantly by co-expression of chaperone GroES-GroEL-Tf. After dual induction and affinity chromatography, purified recombinant CD137L was obtained at a yield of 3 mg protein per liter with purity greater than 98% from original undetectable level. Additionally, the purified recombinant CD137L could bind CD137-positive cells in a dose-dependent manner, markedly promote the growth of activated mice T cells, and elevate the release of IL-2. The present work provides an effective system for soluble expression of functional human co-stimulatory molecule CD137L, which will facilitate the clinical developments of recombinant protein drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997275     DOI: 10.1007/s10295-011-1045-1

Source DB:  PubMed          Journal:  J Ind Microbiol Biotechnol        ISSN: 1367-5435            Impact factor:   3.346


  17 in total

1.  Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity.

Authors:  Catherine Rabu; Agnès Quéméner; Yannick Jacques; Klara Echasserieau; Patricia Vusio; François Lang
Journal:  J Biol Chem       Date:  2005-10-04       Impact factor: 5.157

Review 2.  T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity.

Authors:  Jeurgen Foell; Becker Hewes; Robert S Mittler
Journal:  Curr Cancer Drug Targets       Date:  2007-02       Impact factor: 3.428

3.  A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Authors:  Rich-Henry Schabowsky; Kutlu G Elpek; Shravan Madireddi; Rajesh K Sharma; Esma S Yolcu; Laura Bandura-Morgan; Robert Miller; Kathryn J MacLeod; Robert S Mittler; Haval Shirwan
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

4.  Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.

Authors:  Gloria H Y Lin; Yuanqing Liu; Thanuja Ambagala; Byoung S Kwon; Pamela S Ohashi; Tania H Watts
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

5.  Molecular and biological characterization of human 4-1BB and its ligand.

Authors:  M R Alderson; C A Smith; T W Tough; T Davis-Smith; R J Armitage; B Falk; E Roux; E Baker; G R Sutherland; W S Din
Journal:  Eur J Immunol       Date:  1994-09       Impact factor: 5.532

Review 6.  The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.

Authors:  David H Lynch
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

Review 7.  Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.

Authors:  K S Peggs; S A Quezada; J P Allison
Journal:  Clin Exp Immunol       Date:  2009-02-18       Impact factor: 4.330

8.  ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages.

Authors:  H Schwarz; J Valbracht; J Tuckwell; J von Kempis; M Lotz
Journal:  Blood       Date:  1995-02-15       Impact factor: 22.113

9.  The structure of the trimer of human 4-1BB ligand is unique among members of the tumor necrosis factor superfamily.

Authors:  Eun-Young Won; Kiweon Cha; Jung-Sue Byun; Dong-Uk Kim; Sumi Shin; Byungchan Ahn; Young Ho Kim; Amanda J Rice; Thomas Walz; Byoung S Kwon; Hyun-Soo Cho
Journal:  J Biol Chem       Date:  2009-12-23       Impact factor: 5.157

10.  Chaperone-based procedure to increase yields of soluble recombinant proteins produced in E. coli.

Authors:  Ario de Marco; Elke Deuerling; Axel Mogk; Toshifumi Tomoyasu; Bernd Bukau
Journal:  BMC Biotechnol       Date:  2007-06-12       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.